Syndromic and etiological classification predicts seizure freedom in childhood and youth onset epilepsy: A population‐based study from the Norwegian Mother, Father, and Child Cohort Study
Epilepsia · 2025
DOI: 10.1111/epi.18672 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Epilepsia, 2025. Verfasst von Truls Vikin und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Epilepsy, Division of Clinical Neuroscience, full member of European Reference Network on Rare and Complex Epilepsies EpiCARE, Os…. Hauptthemen laut MEDLINE: Epilepsy, Seizures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Foundation Dam, South-Eastern Norway Regional Health Authority, Helse Sør-Øst RHF.
Abstract (Originalsprache)
Objective
This study was undertaken to determine the proportion of individuals with childhood and youth onset epilepsy who attain seizure freedom across seizure types, epilepsy types, etiologies, and syndromes using the latest International League Against Epilepsy (ILAE) classifications. Secondary objectives were to identify predictors of seizure freedom, evaluate time to last seizure among those achieving it, and estimate prevalence of active epilepsy.
Methods
We used data from the Norwegian Mother, Father, and Child Cohort Study, a nationwide population‐based cohort of ~114 000 children born 1999–2009. Pediatric epileptologists validated and classified epilepsy cases through medical record review. Analyses included 1044 individuals with ≥12 months of follow‐up. Seizure freedom was ≥12 months without seizures, with or without antiseizure medication (ASM), at end of follow‐up. Predictors of seizure freedom were assessed using log‐binomial regression adjusted for follow‐up. Time to last seizure was analyzed using Accelerated Failure Time models. Active epilepsy at any age was defined as seizures during the preceding 2 years and/or ASM use at that age; prevalence was calculated annually from ages 0 to 18 years.
Results
Median follow‐up was 10.6 years. A total of 78% achieved seizure freedom. Predictors of reduced likelihood of seizure freedom included early (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Center for Epilepsy, Division of Clinical Neuroscience, full member of European Reference Network on Rare and Complex Epilepsies EpiCARE, Oslo University Hospital, Oslo, Norway.
- Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
- Royal Hospital for Children and Young People, Edinburgh, UK.
- Muir Maxwell Epilepsy Centre, Institute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK.
- Norwegian Institute of Public Health, Oslo, Norway.
ORCID-Profile: Truls Vikin, Richard F Chin, Morten I Lossius, Dag Hofoss, Ragnhild E Brandlistuen
Förderung
- Foundation Dam
- South-Eastern Norway Regional Health Authority
- Helse Sør-Øst RHF
Zitieren
APA
Vikin, T., Chin, R. F., Lossius, M. I., Hofoss, D., Brandlistuen, R. E., & Aaberg, K. M. (2025). Syndromic and etiological classification predicts seizure freedom in childhood and youth onset epilepsy: A population‐based study from the Norwegian Mother, Father, and Child Cohort Study. Epilepsia. https://doi.org/10.1111/epi.18672
Vancouver
Vikin T, Chin RF, Lossius MI, Hofoss D, Brandlistuen RE, Aaberg KM. Syndromic and etiological classification predicts seizure freedom in childhood and youth onset epilepsy: A population‐based study from the Norwegian Mother, Father, and Child Cohort Study. Epilepsia. 2025. doi:10.1111/epi.18672
BibTeX
@article{Vikin2025,
author = {Vikin, Truls and Chin, Richard F and Lossius, Morten I and Hofoss, Dag and Brandlistuen, Ragnhild E and Aaberg, Kari M},
title = {Syndromic and etiological classification predicts seizure freedom in childhood and youth onset epilepsy: A population‐based study from the Norwegian Mother, Father, and Child Cohort Study},
journal = {Epilepsia},
year = {2025},
doi = {10.1111/epi.18672}
}
EUVIMED